Tuesday, August 31, 2010

New Report Monoclonal Antibodies Market (2010 - 2015) Published By MarketsandMarkets

The global market for diagnostic and therapeutic market is expected to exceed $ 25 million market by the end of 2010. mAbs held the top 3 ranks among the top selling brands in 2008. Monoclonal antibodies present significant opportunities as they are targeted therapy (They impact only the diseased cells and do not harm healthy cells) unlike chemotherapy drugs. This results in reduced side effects and increased effectiveness. Cancer in one of the significant application area for mAbs. However, price correction would enable significant shift of usage from traditional chemotherapy drugs to mAbs
Browse in-depth ToC on Monoclonal Antibodies Market (2010 – 2015)
Early buyers will receive 10% customization of reports 
MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategic advisory reports and serve as a business intelligence partner to Fortune 500 companies across the globe. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.
M&M Banking and Financial Services Practice recognize the challenges that financial institutions face while bringing the right products to market. Our reports and consulting practice provides a unique perspective allowing financial institutions to understand and strategize to achieve their product goals. Through a mix of case studies, primary research, and business modeling we provide a 360° view to identify how our clients can create, capture, and retain the value of their products and outthink the competition.
Ms. Sunita
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Email: sales@marketsandmarkets.com

No comments: